Literature DB >> 10960173

Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion.

C H Kocken1, D L Narum1, A Massougbodji, B Ayivi, M A Dubbeld, A van der Wel, D J Conway, A Sanni, A W Thomas.   

Abstract

Apical membrane antigen 1 is a candidate vaccine component for malaria. It is encoded by a single copy gene and has been characterised in a number of malaria species as either an 83-kDa de novo product (Plasmodium falciparum; Pf AMA-1) or a 66-kDa product (all other species). All members of the AMA-1 family are expressed during merozoite formation in maturing schizonts and are initially routed to the rhoptries. Processed forms may subsequently be associated with the merozoite surface. Because of the unique occurrence of the 83-kDa form in P. falciparum we were interested to determine whether the phylogenetically closely related chimpanzee malaria Plasmodium reichenowi shared characteristics with Pf AMA-1. Here we show that the molecular structure, the localisation and processing are similar to that of Pf AMA-1 and that in vitro growth inhibitory mAbs reactive with Pf AMA-1 also inhibit P. reichenowi growth in an in vitro assay. Polymorphism in the 83-kDa AMA-1 family was analysed through comparison of Pr ama-1 with Pf ama-1 alleles, which showed the most significant evidence for selection maintaining polymorphism in Domains I-III of AMA-1 in P. falciparum. The most substantial divergence between Pr AMA-1 and Pf AMA-1 sequences was in the N-terminal region unique to the 83-kDa form of AMA-1. It was confirmed that the specific Pr ama-1-type allele was not present among P. falciparum parasites in an African population, and an allele coding for lysine at amino acid 187 was uniquely associated with field isolates in this population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960173     DOI: 10.1016/s0166-6851(00)00250-4

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  36 in total

1.  Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene.

Authors:  S D Polley; D J Conway
Journal:  Genetics       Date:  2001-08       Impact factor: 4.562

2.  Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1.

Authors:  Alfred Cortés; Mata Mellombo; Ivo Mueller; Ariadna Benet; John C Reeder; Robin F Anders
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

3.  Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.

Authors:  Markus S Mueller; Annabelle Renard; Francesca Boato; Denise Vogel; Martin Naegeli; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

4.  Independent translocation of two micronemal proteins in developing Plasmodium falciparum merozoites.

Authors:  Julie Healer; Simon Crawford; Stuart Ralph; Geoff McFadden; Alan F Cowman
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

5.  Conditional expression of Toxoplasma gondii apical membrane antigen-1 (TgAMA1) demonstrates that TgAMA1 plays a critical role in host cell invasion.

Authors:  Jeffrey Mital; Markus Meissner; Dominique Soldati; Gary E Ward
Journal:  Mol Biol Cell       Date:  2005-07-06       Impact factor: 4.138

6.  The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.

Authors:  A M Coley; K Parisi; R Masciantonio; J Hoeck; J L Casey; V J Murphy; K S Harris; A H Batchelor; R F Anders; M Foley
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

7.  Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.

Authors:  Faith H A Osier; Gareth D Weedall; Federica Verra; Linda Murungi; Kevin K A Tetteh; Pete Bull; Bart W Faber; Ed Remarque; Alan Thomas; Kevin Marsh; David J Conway
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

8.  Erythrocyte invasion by Babesia bovis merozoites is inhibited by polyclonal antisera directed against peptides derived from a homologue of Plasmodium falciparum apical membrane antigen 1.

Authors:  Fasila R Gaffar; Ana P Yatsuda; Frits F J Franssen; Erik de Vries
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 9.  Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

Authors:  S L Takala; C V Plowe
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

10.  A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.

Authors:  Issaka Sagara; Ruth D Ellis; Alassane Dicko; Mohamed B Niambele; Beh Kamate; Ousmane Guindo; Mahamadou S Sissoko; Michael P Fay; Merepen A Guindo; Ousmane Kante; Renion Saye; Kazutoyo Miura; Carole Long; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kelly Rausch; Amagana Dolo; Dapa A Diallo; Louis H Miller; Ogobara K Doumbo
Journal:  Vaccine       Date:  2009-10-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.